TGTX Stock: Price, Earnings History and SEC Filings
TG Therapeutics, Inc. (TGTX) last traded at $61.18, up 5.34% on the latest session and up 9.7% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.05 against an analyst estimate of $0.41, a miss of 87.8%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
TGTX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 3, 2026 | $0.05 | $0.41 | -87.80% |
| Mar 2026 | May 6, 2026 | $0.17 | $0.23 | -26.09% |
| Dec 2025 | Feb 26, 2026 | $0.14 | $0.35 | -60.00% |
| Sep 2025 | Nov 3, 2025 | $2.43 | $0.24 | +912.50% |
TGTX beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
How TGTX reacts to earnings
Across its last 8 earnings releases, TGTX moved 11.2% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-03 | Before open | -11.26% |
| 2026-05-06 | Before open | +16.26% |
| 2026-02-26 | Before open | +4.18% |
| 2025-11-03 | Before open | -3.13% |
| 2025-08-04 | Before open | -17.99% |
| 2025-05-05 | Before open | -13.26% |
| 2025-03-03 | Before open | +14.39% |
| 2024-11-04 | Before open | -9.44% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
TGTX financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $616M | $447M | -$25M | 72.6% | $2.77 |
| 2024 | $329M | $23M | -$41M | 7.1% | $0.15 |
| 2023 | $234M | $13M | -$31M | 5.4% | $0.09 |
| 2022 | $3M | -$224M | -$176M | -8036.3% | $-1.65 |
| 2021 | $7M | -$348M | -$296M | -5204.1% | $-2.63 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for TGTX
- 10-Q · Aug 5, 2026
- 8-K · Aug 3, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 12, 2026Shareholder vote
- 8-K · Jun 3, 2026Other events, Financial statements and exhibits
- 8-K · May 27, 2026Other events, Financial statements and exhibits
- 10-Q · May 6, 2026
- 8-K · May 6, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 30, 2026
- 8-K · Mar 20, 2026Material agreement, New financial obligation, Financial statements and exhibits
- 10-K · Feb 27, 2026
Insider filing activity
TGTX insiders filed 2 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
TGTX news
- EBay Leads Five Stocks Near Buy Points From Resilient SectorsOct 31, 2026 · finance.yahoo.com
- TG Therapeutics Is Up 98%, But The Story Isn't FinishedOct 30, 2026 · finance.yahoo.com
- TGTX Stock Hits Fresh 52-Week High Ahead Of Earnings Amid Buyout BuzzOct 30, 2026 · stocktwits.com
- GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales GrowthOct 30, 2026 · finance.yahoo.com
- INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised GuidanceOct 30, 2026 · finance.yahoo.com
- Edwards' Q3 Earnings on the Horizon: What's in the Cards?Oct 30, 2026 · finance.yahoo.com
- INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View RaisedOct 29, 2026 · finance.yahoo.com
- VKTX Q3 Earnings Miss Estimates Amid Rising Clinical ExpensesOct 29, 2026 · finance.yahoo.com
About TG Therapeutics, Inc.
TG Therapeutics, Inc. (TGTX) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.